A Genetic Switch That May Turn Up Immune Attack on Insulin-Producing Cells

Our immune systems have built-in safety mechanisms to prevent them from attacking the body's own cells. One key safety switch is a protein called CD47, found on many healthy cells. When CD47 is present, it sends a signal that essentially says 'don't attack me.' Immune cells that receive this signal stand down.

A new study published in NPJ Autoimmunity reveals that in people with Type 1 diabetes risk variants in a gene called SIRPG, this protective signal weakens on immune cells themselves. Specifically, people carrying these risk variants have higher amounts of SIRP gamma (a protein made by the SIRPG gene) and lower amounts of CD47 on their T cells—the immune cells that orchestrate much of the autoimmune response.

To understand what happens when CD47 is missing, researchers used CRISPR gene-editing technology to create immune cells and pancreatic beta cells without CD47. The results were striking: immune cells lacking CD47 became hyperactive. They expressed fewer 'co-inhibitory receptors'—other safety mechanisms that normally calm immune responses—and produced more inflammatory molecules like IL-2 and TNF.

More importantly, CD8+ T cells without CD47 became more effective killers. When researchers added beta cells that also lacked CD47, the immune cells attacked them with greater intensity. This dual vulnerability—aggressive immune cells paired with less-protected beta cells—suggests why this genetic variant might increase Type 1 diabetes risk.

This research provides a clearer picture of one pathway through which Type 1 diabetes develops. By identifying that CD47 acts as a restraint on autoimmune attack in genetically susceptible people, scientists now have a specific target to explore. Future therapies might work by restoring or enhancing this protective signal.

The findings also highlight why genetics alone do not determine who develops Type 1 diabetes. The risk variants alter immune cell behavior in ways that increase vulnerability, but other factors—including environmental triggers and the strength of other protective mechanisms—likely determine whether disease actually develops in any individual.

Source: NPJ autoimmunity. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.